UK Scientist Develops Simulated Human Heart to Test Drugs\' Effects before Clinical Trials
Aquavit Pharmaceuticals, Inc. has introduced an innovative technology known as AQUAGOLD® fine touch™, which represents a groundbreaking advancement in direct dermal application.
Helen Maddock, a scientist affiliated with the Centre for Applied Biological and Exercise Sciences at Coventry University, UK, has developed a novel technique that enables the safe testing of a drug's cardiovascular effects even before it progresses to animal or human trials.
This pioneering technique, called the "simulated" cardiovascular system or work-loop assay, allows for the early assessment of drugs and the identification of any potential negative effects.
The method involves utilizing a realistic model of the heart muscle's dynamics. It incorporates samples of beating heart tissue attached to a specialized apparatus that facilitates the muscle's contraction and relaxation while being stimulated by electrical impulses. By introducing trial drugs to the tissue, scientists can observe if there are any adverse effects on the heart muscle's ability to contract.
This ensures that drugs undergo testing at an early stage, even before animal or human trials commence.
The technique employs an in vitro approach, which means it is conducted within a laboratory setting rather than within a living organism. The objective is to enhance the quality of treatment and ultimately save the lives of numerous patients.
